Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,

Slides:

Advertisements

Similar presentations

ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,

Advertisements

Oncologic Drugs Advisory Committee

O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.

The stroke and aphasia quality of life scale (SAQOL-39g) in Greek: Psychometric evaluation K. Hilari1, 3, E. Efstratiadou1,3, M. Ignatiou1, V. Christaki1,

1 QOL in oncology clinical trials: Now that we have the data what do we do?

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Fabrice Barlési Thoracic Oncology Pôle Cardiovasculaire et Thoracique & EA3279 Marseille - France ERS live lecture – May 21, 2008 Quality of Life in Lung.

L1:Apply the concepts of health and wellness to identify health behaviours and factors influencing choice and change in health using an holistic approach.

1 Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims Ann Marie Trentacosti, M.D. Study Endpoints and Labeling Office of New Drugs Food.

Patient-Reported Outcomes: Introducion and Overview Pythia Nieuwkerk, PhD Department of Medical Psychology Academic Medical Center, Amsterdam.

Rehabilitative care approach in a specialist palliative day care centre: a study of patient’s perspectives Author: C.A. Belchamber October 2003.

CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Indicators of health and disease frequency measures

Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.

…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.

Patient Reported Outcomes in Oncology Trials Virginia Kwitkowski Clinical Reviewer-- FDA Division of Drug Oncology Products Member OND Patient Reported.

BC Jung A Brief Introduction to Epidemiology - XI (Epidemiologic Research Designs: Experimental/Interventional Studies) Betty C. Jung, RN, MPH, CHES.

Rare Diseases and PROMIS : Opportunities Natcher Conference Center March 1, 2013 James Witter MD, PhD FACR CSO PROMIS Medical Officer: Rheumatic Diseases.

1 Rachel Torres, MPH, CHES Department of Health & Behavior Studies Teachers College, Columbia University Relationships between Health Literacy, Self- efficacy.

Patient-Reported Outcomes Measurement Information System (PROMIS): Opportunities in Health Services Research Steven Clauser, Ph.D. National Cancer Institute.

Copyright © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 12 Undertaking Research for Specific Purposes.

Selection of a Survey Instrument for a Heart Failure Disease Management Study Lee R. Goldberg, MD, MPH Heart Failure/Transplant program University of Pennsylvania.

FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

EPE C for VE T E R A N S EPE C for VE T E R A N S Education in Palliative and End-of-life Care for Veterans is a collaborative effort between the Department.

Phase III studies of Xeloda® in colorectal cancer (CRC)

PATIENT REPORTED OUTCOMES Albert W. Wu, MD, MPH Joseph Finkelstein, MD, PhD, MA, CCRP ICTR Clinical Registry Workshop, 10 November 2010.

Healthcare Philosophies. What are they? As with many things in life there are a few different approaches to medical knowledge. Think of it like different.

Introduction Patients with tumors affecting the spine have significant impairments in Quality of Life domains that include physical function, neural function,

CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.

#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.

Exploring the Business and Clinical Cases for Screening for Health Literacy in Primary Care: A Case Study Using the NVS Jonathan B. VanGeest, PhD School.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

Lecture 6: Reliability and validity of scales (cont) 1. In relation to scales, define the following terms: - Content validity - Criterion validity (concurrent.

Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.

Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.

BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.

Medical Knowledge Systems. What are they? As with many things in life there are a few different approaches to medical knowledge. Think of it like different.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Health-related quality of life in patients with oesophageal- and gastric cancer Lovisa Backemar, MD Surgical Care Sciences Department of Molecular Medicine.

Whose Life is it Anyway? Proxy v. Self reported quality of life in Childhood Cancer Survivors Penney Upton.

Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant.

Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.

Quality of life and its health- relations. Definitions.

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.

Comparing and Validating Simple Measure of Patient-reported Peripheral Neuropathy for NCCTG Clinical Trials: a Pooled Analysis of 2440 Patients Heshan.

NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Symptom Benefit Study Measuring the Benefit of Palliative Chemotherapy.

Performing a Successful Supportive Care Clinical Trial Jennifer Temel, MD.

Developing and Implementing Intervention Studies Using Geriatric Assessment Supriya Gupta Mohile, M.D., M.S. Assistant Professor of Medicine James Wilmot.

CoRPS Nice Center of Research on Psychology in Somatic diseases Quality of life and symptom assessment in long-term blood cancer survivors (chapter.

CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?

Got outcome measures? What Clinicians & Investigators Want Lisa M. Shulman, M.D. The Eugenia Brin Professor in Parkinson’s Disease and Movement Disorders.

CIPN: Considerations for Drug Development

TEXILA AMERICAN UNIVERSITY

Evidence-based Medicine

CLINICAL PROTOCOL DEVELOPMENT

Quality of Life Assessment

CCO Independent Conference Coverage

Measurement Wu Gong, MS, MD

Critical Reading of Clinical Study Results

Comments on Methodological Challenges in Clinical Trials for CIPN Scott Evans, PhD, MS Harvard University ACTTION, 2017.

Communication Skills Lecture 1-2

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

International Perthes Study Group

Presentation transcript:

Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH, DHHS

What Is A Patient Reported Outcome? A Patient Reported Outcome (PRO) is a measurement of any aspect of a patient’s health status that comes directly from the patient, without interpretation of the patient’s responses by a clinician or research associate

What Is Quality of Life? Quality Of Life is an assessment by a person of all aspects of life Health Related QOL (HRQL) is an assessment of how illness and its treatment affect a person’s well being (≥ 3 domains: physical, mental, and social functioning, etc).

PRO ≠ QOL ≠ HRQL Evaluation of impact of illness or treatment on physical, emotional, & social aspects of QOL Evaluation of all aspects of life Anything reported by the patient Quality of Life QOL Patient Reported Outcomes PROs Health-Related Quality of Life HRQL

Wilson and Cleary’s HRQOL Conceptual Model Biological and Physiological Variables Overall Quality of Life General Health Perceptions Symptoms Status Functional Status Characteristics of the Individual Characteristics of the Environment

Mayo Clinic Example: What is Your Overall Quality of Life? Hospice patients 7.6 Advanced cancer patients 7.2 Recovering surgical patients 6.6 Healthy volunteers 8.2 Medical students 4.4

Why Measure QOL in Cancer Trials? To determine a winner if treatment outcomes equivalent To determine the effect of cancer or its treatment on other aspects of life (ripple effect). To obtain patients’ perspective of therapy and its impact. QOL assessment can provide powerful data on symptoms and toxicity. But, what is the relevant information to be obtained from QOL?

What Question Are You Asking? How Does that Information Help? Answers may differ with disease stage What’s applicable in the adjuvant setting may not be applicable in metastatic disease or prevention setting Questionnaires bring the patient’s perspective. Impact of therapy on ability to function Impact of toxicity (short or long term) Will that information help physicians & patients make better decisions regarding therapy? Clinical significance

Key Questions When Incorporating QOL/PRO Outcomes in Clinical Trials: What is the purpose of the QOL/PRO assessment? How will a QOL/PRO assessment add to the information from the trial? What are the key QOL or symptom specific issues identified by the investigators? Will existing QOL/PRO tools be appropriate for the trial?

“How will a QOL or PRO assessment add to the information from the trial?” GOG 179: Cisplatin with or without topotecan in advanced cervical cancer C+T = > PFS and OS with More Toxicity No significant QOL; stable over time Use of reliable assessment instrument longitudinally allows favoring combination chemo to single-agent in this population

“Will QOL information help us make better decisions regarding therapy?” GOG172: Pts who received higher dose IP therapy, compared to those with conventional dose IV therapy experienced better survival

Patient-Reported FACT-O Scores (1)

Patient-Reported FACT-O Scores (2)

“Is It Possible to Obtain Patient’s Perspective of therapy and its Impact?” QOL data useful in interpreting treatment implications and influencing decision-making Illustrates complex relationship between treatment efficacy and toxicity (e.g., 179) More precise estimation of toxicity (e.g., Ntx) Supports development of more acceptable treatment alternatives (e.g., 172)